Mmadụ BCR-ABL Fusion Gene Mutation

Myelogenousleukemia na-adịghị ala ala (CML) bụ ọrịa na-adịghị mma nke clonal nke mkpụrụ ndụ sel hematopoietic.Ihe karịrị 95% nke ndị ọrịa CML na-ebu chromosome Philadelphia (Ph) n'ime sel ọbara ha.Ihe na-ebutekarị ọrịa CML bụ nke a: A na-emepụta mkpụrụ ndụ BCR-ABL site na ntụgharị n'etiti abl proto-oncogene (Abelson murine leukemia viral oncogene homolog 1) na ogwe aka ogologo nke chromosome 9 (9q34) na mpaghara ụyọkọ breakpoint ( BCR) gene na ogologo ogwe aka nke chromosome 22 (22q11);protein fusion nke mkpụrụ ndụ ihe nketa a na-etinye na ya nwere ọrụ tyrosine kinase (TK), ma na-eme ka ụzọ mgbaàmà ya dị n'okpuru (dịka RAS, PI3K, na JAK/STAT) iji kwalite nkewa sel na igbochi apoptosis cell, na-eme ka mkpụrụ ndụ na-amụba nke ọma, wee si otú ahụ mee ka ọ dịkwuo njọ. ihe omume CML.BCR-ABL bụ otu n'ime ihe nrịbama nchoputa dị mkpa nke CML.Mgbanwe dị egwu nke ọkwa ederede ya bụ ihe ngosi a pụrụ ịdabere na ya maka ikpe gbasara ọrịa leukemia ma nwee ike iji kọwaa nlọghachi nke leukemia mgbe ọgwụgwọ gasịrị.